Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
BONE BIOLOGICS CORP (BBLG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.32-6.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BBLG yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Free cash flow moves towards breakeven | A supporting condition in BONE BIOLOGICS CORP's published investment case. The stated target is Free cash flow yield improves to >= -0.3%. | Broken | Free cash flow yield remains below -0.6% beyond FY27 | Valuation inputs unavailable A completed valuation measurement is required. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth thesis, not a proven durable business, because the evidence describes the company as loss-making and high risk. The signal has turned mildly favorable and momentum has improved, but the thesis remains on watch and confidence is low.
The evidence does not provide a valuation measure or a clear account of what the market expects, so whether BBLG is cheap or expensive versus peers is unclear. The available signals point to caution around the company’s financial performance, rather than a defined expectations gap.
Over the near term, results and guidance remain uncertain, with elevated risk of an earnings miss; financial performance is below its industry cohort. Over the multi-year view, progress depends on advancing the NB1 clinical program, completing pilot study enrollment, improving product stability and manufacturing readiness, and extending operating runway through Q2 2027.
A guidance cut on the next call or further weakening in job growth would add pressure to an already high-risk thesis. Continued strength from Healthcare sector bellwethers could support sector momentum, while execution on NB1 and capital discipline remain key company-specific swing factors.
The 1-to-3-year view is uncertain: recent signals have improved, but losses, execution needs, and near-term reporting risk leave the thesis on watch. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in BONE BIOLOGICS CORP's published investment case. The stated target is EPS loss narrows to >= -1.26 USD per share. |
| Improving |
| EPS loss does not improve beyond -1.93 USD per share by FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Start generating measurable revenue | A primary condition in BONE BIOLOGICS CORP's published investment case. The stated target is Revenue > 0 USD. | Intact | Revenue remains at zero through FY27 | Revenue: $0 FY2026-Q3; GAAP. Published target: Revenue > 0 USD. Annual target cannot be compared with a quarterly or TTM observation. Oct 26, 20260 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.64 → $-0.59 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-25 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-26 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-27 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-28 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-29 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-30 | $-0.64 | $0 | 1 / 1 |
| 2026-07-31 | $-0.64 | $0 | 1 / 1 |
| 2026-08-01 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-02 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-03 | $-0.64 | $0 | 1 / 1 |
| 2026-08-04 | $-0.64 | $0 | 1 / 1 |
| 2026-08-05 | $-0.64 | $0 | 1 / 1 |
| 2026-08-06 | $-0.64 | $0 | 1 / 1 |
| 2026-08-07 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-08 | $-0.64 | $0 | 1 / 1 |
| 2026-08-09 | $-0.64 | $0 | 1 / 1 |
| 2026-08-10 | $-0.64 | $0 | 1 / 1 |
| 2026-08-11 | $-0.64 | $0 | 1 / 1 |
| 2026-08-12 | $-0.64 | $0 | 1 / 1 |
| 2026-08-13 | $-0.64 | $0 | 1 / 1 |
| 2026-08-14 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-15 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-16 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-17 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-18 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-19 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-20 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-21 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-22 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-23 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-24 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-25 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-26 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-27 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-28 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-29 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-30 | $-0.67 | Unavailable | 1 / 0 |
| 2026-08-31 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-01 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-02 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-03 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-04 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-05 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-06 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-07 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-08 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-09 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-10 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-11 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-12 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-13 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-14 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-15 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-16 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-17 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-18 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-19 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-20 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-21 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-22 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-23 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-24 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-25 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-26 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-27 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-28 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-29 | $-0.67 | Unavailable | 1 / 0 |
| 2026-09-30 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-01 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-02 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-03 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-04 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-05 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-06 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-07 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-08 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-09 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-10 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-11 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-12 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-13 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-14 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-15 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-16 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-17 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-18 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-19 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-20 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-21 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-22 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-23 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-24 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-25 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-26 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-27 | $-0.67 | Unavailable | 1 / 0 |
| 2026-10-28 | $-0.59 | Unavailable | 1 / 0 |
| 2026-10-29 | $-0.59 | Unavailable | 1 / 0 |
| 2026-10-30 | $-0.59 | Unavailable | 1 / 0 |
| 2026-10-31 | $-0.59 | Unavailable | 1 / 0 |
| 2026-11-01 | $-0.59 | Unavailable | 1 / 0 |
| 2026-11-02 | $-0.59 | Unavailable | 1 / 0 |
| 2026-11-03 | $-0.59 | Unavailable | 1 / 0 |
| 2026-11-04 | $-0.59 | Unavailable | 1 / 0 |
| 2026-11-05 | $-0.59 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.